Cargando…

The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations

The uncommon mutations in the EGFR (the epithelial growth factor receptor) gene include a heterogeneous group of genomic alterations within exons 18-21. The clinical response of patients with such mutations to EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment, however, remains unclear. We herein r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Watanabe, Masahiro, Oizumi, Satoshi, Kiuchi, Shizuka, Yamada, Noriyuki, Yokouchi, Hiroshi, Fukumoto, Shinichi, Harada, Masao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919859/ https://www.ncbi.nlm.nih.gov/pubmed/29225262 http://dx.doi.org/10.2169/internalmedicine.9565-17

Ejemplares similares

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

Response to: Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Citarella, Fabrizio, et al.
Publicado: (2021)

Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations
por: Nasu, Shingo, et al.
Publicado: (2018)

Exploring the conformational dynamics and thermodynamics of EGFR S768I and G719X + S768I mutations in non-small cell lung cancer: An in silico approaches
por: Wang, Jun-Ling, et al.
Publicado: (2023)

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

Successful Resection of G719X-Positive Pleomorphic Carcinoma after Afatinib Treatment
por: Nakamura, Daisuke, et al.
Publicado: (2017)

A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma
por: Morimoto, Toshiki, et al.
Publicado: (2023)

Gefitinib-induced hemorrhagic cystitis and inflammatory contracted bladder in a patient with advanced lung adenocarcinoma harboring compound epidermal growth factor receptor G719S and S768I missense mutations: a case report
por: Bai, Xueli, et al.
Publicado: (2022)

Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report
por: Ma, Chunhua, et al.
Publicado: (2020)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
por: Kulkarni, Amit A, et al.
Publicado: (2022)

Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report
por: Cai, Yangyang, et al.
Publicado: (2020)

Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report
por: Duan, Hua, et al.
Publicado: (2018)

Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
por: Watanabe, Satoshi, et al.
Publicado: (2014)

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
por: Wu, Shang-Gin, et al.
Publicado: (2020)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Unique characteristics of G719X and S768I compound double mutations of epidermal growth factor receptor (EGFR) gene in lung cancer of coal-producing areas of East Yunnan in Southwestern China
por: Wang, Jun-Ling, et al.
Publicado: (2022)

ZNF768 Expression Associates with High Proliferative Clinicopathological Features in Lung Adenocarcinoma
por: Poirier, Audrey, et al.
Publicado: (2021)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

EGFR (p. G719A+L747V)/EML4-ALK Co-alterations in Lung Adenocarcinoma with Leptomeningeal Metastasis Responding to Afatinib Treatment: A Case Report
por: Lu, Zhiqin, et al.
Publicado: (2021)

768. Gaining Compliance-Getting Results
por: Staton, Sharon, et al.
Publicado: (2021)

Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
por: Zhou, Bin, et al.
Publicado: (2022)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

Case Report: The effective treatment of patients in advanced no-small cell lung cancer patients with EGFR G719X/S768I/L861Q and acquired MET amplification: A case series and literature review
por: Zhao, Yun, et al.
Publicado: (2023)

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
por: Villaruz, L.C., et al.
Publicado: (2023)

Durable response to afatinib in advanced lung adenocarcinoma harboring a novel NPTN-NRG1 fusion: a case report
por: Nie, Xin, et al.
Publicado: (2023)

Prolonged response to first‐generation tyrosine kinase inhibitor in a metastatic non‐small cell lung cancer harbouring complex G719X and S768I mutations: A case report from Vietnam and literature review
por: Do, Kien Hung, et al.
Publicado: (2023)

The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Poster Sessions 555 - 719
Publicado: (2003)

Afatinib as first‐line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature
por: Shi, Yuequan, et al.
Publicado: (2018)

The effect of afatinib in a pretreated patient with invasive mucinous adenocarcinoma of the lung harboring HER2 YVMA insertion: a case report
por: He, Yueming, et al.
Publicado: (2022)

Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report
por: Kong, Chen, et al.
Publicado: (2020)

Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

ZNF768 links oncogenic RAS to cellular senescence
por: Villot, Romain, et al.
Publicado: (2021)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER2 oncogene alterations
por: Suzawa, Ken, et al.
Publicado: (2015)

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
por: Zhang, Shannon S, et al.
Publicado: (2022)

Corrigendum: Afatinib for Advanced Non-small Cell Lung Cancer in a Case With an Uncommon Epidermal Growth Factor Receptor Mutation (G719A) Identified in the Cerebrospinal Fluid
por: Ma, Chunhua, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_23ems6dame45mjmn8srq5hr25p